Search
for
Sort by
Research 121–150 of 1000+
- EGFR Inhibitors and Cutaneous Complications: A Practical Approach to Management
- Cutaneous Lesions in the Rat Following Administration of an Irreversible Inhibitor of erbB Receptors, Including the Epidermal Growth Factor Receptor
- New small molecules in dermatology: for the autoimmunity, inflammation and beyond
- EGFR inhibitor-induced folliculitis decalvans: a case series and management guidelines
- Management of Toxicities of Targeted Therapies
- Developing a JAK Inhibitor for Targeted Local Delivery: Ruxolitinib Cream
- Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
- Epidermal Growth Factor Receptor Inhibitors: A Review of Cutaneous Adverse Events and Management
- Chemotherapy-induced iatrogenic injury of skin: New drugs and new concepts
- The trichoscopic features of hair shaft anomalies induced by epidermal growth factor receptor inhibitors: A case series
- Novel Janus Kinase Inhibitors in the Treatment of Dermatologic Conditions
- A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results
- Preclinical Pharmacology, Antitumor Activity, and Development of Pharmacodynamic Markers for the Novel, Potent AKT Inhibitor CCT128930
- Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib
- Advances in the Management of Cutaneous Toxicities of Targeted Therapies
- Cutaneous side-effects of EGFR inhibitors and their management.
- Under Development JAK Inhibitors for Dermatologic Diseases
- Expression Profiles of Tyrosine Kinases in Cultured Follicular Papilla Cells Versus Dermal Fibroblasts
- Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Post-marketing safety signals of four JAK inhibitors for alopecia areata: an indication-restricted FAERS pharmacovigilance study
- Janus kinase inhibitors for alopecia areata: A narrative review
- Use of Jak Inhibitors in the Treatment of Alopecia Areata
- Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
- TYK2 Inhibition with Deucravacitinib Improves Clinical Outcomes and Resolves Interferon-Driven Inflammation in Lichen Planopilaris
- Clinical evidence for JAK inhibition in alopecia areata: A comprehensive review
- Turning JAK STATic, a peek into the future of dermatology therapeutics
- Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
- Which is the ideal JAK inhibitor for alopecia areata – Baricitinib, tofacitinib, ritlecitinib or ifidancitinib - Revisiting the immunomechanisms of the JAK pathway
- PRIDE syndrome with lumbosacral hypertrichosis